**SOLID TUMOURS**

**DISEASE**

Note: complete this form only if this diagnosis was the indication for the HCT/CT or if it was specifically requested. Consult the manual for further information.

**Date of diagnosis:** ____/__/__(YYYY/MM/DD)

**Classification:**
- [ ] Bone sarcoma (excluding Ewing sarcoma/PNET)
- [ ] Breast
- [ ] Central nervous system tumours (include CNS PNET)
- [ ] Ewing sarcoma (ES)/PNET, extra-skeletal
- [ ] Ewing sarcoma(ES)/PNET, skeletal
- [ ] Ewing sarcoma(ES)/PNET, not classified
- [ ] Germ cell tumour, extragonadal only
- [ ] Germ cell tumour, gonadal
- [ ] GI tract and Hepatopancreatic cancer
- [ ] Kidney cancer excluding Wilms' tumour
- [ ] Lung cancer, non-small cell (NSCLC)
- [ ] Lung cancer, small cell
- [ ] Medulloblastoma
- [ ] Melanoma
- [ ] Nasopharyngeal carcinoma
- [ ] Neuroblastoma
- [ ] Ovarian (carcinoma)
- [ ] Prostate
- [ ] Retinoblastoma
- [ ] Rhabdomyosarcoma
- [ ] Soft tissue sarcoma (excluding Rhabdo and extra-skeletal ES)
- [ ] Thymoma
- [ ] Wilms' tumour
- [ ] Other; specify: ____________________

**TNM classification:**

<table>
<thead>
<tr>
<th>Type</th>
<th>Tumour</th>
<th>Nodes</th>
<th>Metastases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical</td>
<td>TX</td>
<td>NX</td>
<td>MX</td>
</tr>
<tr>
<td></td>
<td>T0</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Pathological</td>
<td>T1</td>
<td>N1</td>
<td>M1</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>N2</td>
<td>Not evaluated</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N3</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>Not evaluated</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>Not evaluated</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Index: Registry 101 | Title: Solid tumours | Version: 1.0 | Effective Date: 2023-08-22 | THIS IS AN UNCONTROLLED COPY
### DISEASE continued

#### Disease-specific staging:

- [ ] I
- [ ] II
- [ ] III
- [ ] IV
- [ ] Not evaluated
- [ ] Unknown

### Breast carcinoma risk factors and staging at diagnosis *(Breast carcinoma only)*:

<table>
<thead>
<tr>
<th>Receptor status</th>
<th>Estrogen (ER):</th>
<th>Negative</th>
<th>Positive: ER values:</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Progesterone (PgR):</td>
<td>Negative</td>
<td>Positive: PgR values:</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>HER2/neu (c-erb-B2):</td>
<td>Negative</td>
<td>Positive</td>
<td>Not evaluated</td>
<td></td>
</tr>
</tbody>
</table>

- Defined by: [ ] IHC 3+ [ ] IHC 1/2+ and FISH+

- Axillary lymph nodes at surgery: N<sup>0</sup> positive / N<sup>0</sup> examined = _____ / _____ [ ] Not evaluated
- Sentinel Node: [ ] Negative [ ] Positive [ ] Not evaluated
- Carcinoma type *(tick only one)*: [ ] Ductal carcinoma [ ] Lobular carcinoma [ ] Other; specify: __________
- Proliferation index (activity by Ki67 or Mib1 immunostaining): __________% of positive cells
- Inflammatory breast cancer: [ ] Yes [ ] No

### Germ cell tumour risk factors and staging at diagnosis *(Germ cell tumours only)*:

<table>
<thead>
<tr>
<th>Histological classification:</th>
<th>Seminoma</th>
<th>Non-seminoma</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>(Note: mixed tumours to be considered as non-seminoma)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Site of origin: [ ] Gonadal
- [ ] Extra-gonadal: [ ] Retroperitoneal [ ] Mediastinal [ ] Other sites; specify: ____________________________